The DEA Is Conflating a Real Drug-Safety Problem With a Ban on People's Last Off-Ramp

On July 1, the DEA filed a Notice of Intent — the formal step that lets the agency temporarily schedule a substance for up to three years without waiting on the full, multi-year rulemaking process — to place 7-hydroxymitragynine into Schedule I of the Controlled Substances Act. Schedule I is the same legal tier as heroin, reserved for drugs the DEA says have no accepted medical use and a high potential for abuse. The target is 7-OH: not kratom itself, but a compound isolated and concentrated out of kratom leaf, then pressed into tablets and sold as “shots” at gas stations and smoke shops. The line the DEA draws is precise — only products above a 0.050% dry-weight threshold, the share of 7-OH in a product’s dried weight, are captured. Raw kratom leaf, where 7-OH occurs naturally at trace levels, is explicitly excluded.

7-OH is not kratom, and the DEA is right to treat it as its own drug — but the scheduling machine keeps punishing the exact people the system already failed.

Two weeks later, Governor Newsom’s office announced that California’s own crackdown had pulled more than 6,700 illegal kratom and 7-OH products off shelves, with 98% compliance among state-licensed retailers, and framed the federal action as Washington finally catching up to California. Then HHS and FDA publicly commended the DEA’s move. It’s a tidy loop: a state claims credit, the feds validate it, everyone gets a press release. It’s also political theater sitting on top of a distinction that theater tends to erase. Concentrating 7-OH out of kratom leaf genuinely changes its pharmacology — it becomes a far more potent, more opioid-like compound, with documented dependence and overdose risk that a cup of kratom tea doesn’t carry at anything close to the same dose. That’s not scaremongering. That’s chemistry.

But Pain News Network reports the people most exposed to this policy aren’t the ones the press releases picture. They’re chronic pain patients and people managing opioid withdrawal or use disorder who turned to kratom or 7-OH because methadone or buprenorphine was unaffordable, inaccessible, or attached to a treatment system that had already burned them once. For that population, a Schedule I listing doesn’t distinguish leaf tea from a concentrated tablet any more precisely than a governor’s press release does — it just removes the option, full stop, with nothing standing in to replace it.

That’s the incoherence worth naming out loud: the DEA’s own notice draws a careful line between botanical kratom and concentrated 7-OH, but the political rollout — a federal ban, a state’s seized-product tally cited as a trophy, an HHS statement offering applause instead of access — collapses that line right back into one undifferentiated “kratom is dangerous” story. Nobody in this chain is funding the buprenorphine access that would make the ban survivable for the people who’ll actually feel it.

Six thousand seven hundred products pulled off shelves is a number worth putting on a press release. It is not a treatment plan for the person who was using one of them to stay off fentanyl.